
    
      This is a Phase I open-label dose escalation study of KW-0761 in relapsed patients with CCR4
      positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell Lymphoma (PTCL). This
      study is designed to evaluate safety, pharmacokinetics, immunogenicity and preliminary
      efficacy. Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended
      Phase II dose (RPIID) have been established.
    
  